P06.05 Myoinositol as a predictive baseline biomarker for overall survival of patients with recurrent glioblastoma treated with Bevacizumab: A 1H-magnetic resonance spectroscopy study.

BACKGROUND: Antiangiogenic treatment of glioblastomas with Bevacizumab (BVZ) lacks predictive markers. Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality. Since BVZ markedly reduces tumor edema, we asked whether the MI concentr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Steidl, E., Pilatus, U., Steinbach, J. P., Zanella, F., Ronellenfitsch, M. W., Hattingen, E., Bähr, O.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
P06 Biomarkers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5782594/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.096
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars